Multivalent Influenza vaccine production in HEK-293 cells in response to pandemic threats


Influenza virus infects millions of people every year worldwide, with elderly and very young people among the most critically affected. Strains that constitute a pandemic threat are characterized by the severity of the clinical manifestations and mortality rates and tend to require the urgent production of hundreds of millions of vaccine doses in very short periods of time. There is an evident need to develop new generations of influenza vaccines based on robust production systems such as mammalian or insect cell cultures. These systems may allow, in contrast to production in embryonated chicken eggs, a faster response capacity, a superior manufacturing process control and a more reliable and better characterized product.

Vaccine Technology VIII, ECI Symposium Series 2022
Professor Amine Kamen
Canada Research Chair in Bioprocessing of Viral Vaccines & National Research Council of Canada Emeritus

My research interests include cell culture engineering, bioprocess optimization and scale-up, and manufacturaing of antiviral vaccines and viral vectors for gene derlivery.